Get the Stockscreener App
3.41
4.92%
0.16
Camp 4 Therapeutics Corp stock is traded at $3.41, with a volume of 48,485.
It is up +4.92% in the last 24 hours and down -9.55% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$3.25
Open:
$3.34
24h Volume:
48,485
Relative Volume:
0.06
Market Cap:
$159.86M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-0.8325
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
-5.80%
1M Performance:
-9.55%
6M Performance:
+79.47%
1Y Performance:
-42.30%
1-Day Range:
$3.14
$3.44
1-Week Range:
$3.14
$3.96
52-Week Range:
$1.305
$10.80
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.41 | 152.36M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Will Camp4 Therapeutics Corporation stock outperform international peersJuly 2025 Technicals & Expert-Curated Trade Recommendations - BỘ NỘI VỤ
How Camp4 Therapeutics Corporation stock valuations compare to rivals2025 Geopolitical Influence & Safe Entry Zone Identification - BỘ NỘI VỤ
CAMP4 Therapeutics Corporation (CAMP) -6.6% in After-hours: Without a Clear Catalyst - Stocks Telegraph
Activity Recap: How Camp4 Therapeutics Corporation stock valuations compare to rivalsQuarterly Growth Report & Free Daily Entry Point Trade Alerts - BỘ NỘI VỤ
[424B3] Camp4 Therapeutics Corp Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
How Camp4 Therapeutics Corporation stock performs in interest rate cyclesEntry Point & Safe Entry Zone Tips - newser.com
Will Camp4 Therapeutics Corporation stock split again soonQuarterly Portfolio Report & Long-Term Investment Growth Plans - newser.com
Chart based exit strategy for Camp4 Therapeutics CorporationQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Best data tools to analyze Camp4 Therapeutics Corporation stock2025 Technical Overview & Reliable Breakout Forecasts - newser.com
Will earnings trigger a reversal in Camp4 Therapeutics Corporation2025 Price Targets & Free Real-Time Volume Trigger Notifications - newser.com
Can Camp4 Therapeutics Corporation stock withstand economic slowdownTrade Risk Assessment & Long-Term Safe Investment Ideas - newser.com
Will Camp4 Therapeutics Corporation stock reach Wall Street targets2025 Retail Activity & Reliable Volume Spike Trade Alerts - newser.com
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
[S-3] Camp4 Therapeutics Corp Shelf Registration Statement | CAMP SEC FilingForm S-3 - Stock Titan
Real time breakdown of Camp4 Therapeutics Corporation stock performance2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
Strategic Focus and Financial Strength Drive Buy Rating for CAMP4 Therapeutics - TipRanks
Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates - Fierce Biotech
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights - The Manila Times
Will Camp4 Therapeutics Corporation stock benefit from upcoming earnings reportsQuarterly Market Review & AI Forecasted Stock Moves - Fundação Cultural do Pará
How moving averages guide Camp4 Therapeutics Corporation tradingQuarterly Portfolio Summary & AI Enhanced Execution Alerts - newser.com
Does Camp4 Therapeutics Corporation qualify in momentum factor screeningQuarterly Profit Review & Long Hold Capital Preservation Plans - newser.com
How Camp4 Therapeutics Corporation stock trades before earningsMarket Movement Recap & Long-Term Investment Growth Plans - newser.com
Risk adjusted return profile for Camp4 Therapeutics Corporation analyzedJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Can Camp4 Therapeutics Corporation stock sustain revenue growthTrade Entry Summary & Proven Capital Preservation Methods - newser.com
Is Camp4 Therapeutics Corporation stock overvalued by current metricsPortfolio Profit Report & Community Verified Watchlist Alerts - Fundação Cultural do Pará
How Camp4 Therapeutics Corporation stock reacts to global recession fearsLayoff News & Smart Swing Trading Techniques - newser.com
Can Camp4 Therapeutics Corporation stock weather global recessionGap Up & Safe Swing Trade Setups - newser.com
Can Camp4 Therapeutics Corporation stock reach $100 price targetCEO Change & Low Risk High Win Rate Picks - newser.com
What to do if you’re stuck in Camp4 Therapeutics CorporationWeekly Gains Summary & Smart Money Movement Alerts - newser.com
How to interpret RSI for Camp4 Therapeutics Corporation stockJuly 2025 Rallies & High Yield Stock Recommendations - newser.com
Volume spikes in Camp4 Therapeutics Corporation stock – what they meanStop Loss & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-10-19 02:06:54 - nchmf.gov.vn
Is Camp4 Therapeutics Corporation stock a safe buy before earningsJuly 2025 Recap & Weekly Momentum Picks - Trung tâm Dự báo KTTV quốc gia
Can Camp4 Therapeutics Corporation stock sustain market leadershipInflation Watch & Stock Portfolio Risk Control - nchmf.gov.vn
Combining price and volume data for Camp4 Therapeutics CorporationJuly 2025 Update & Real-Time Chart Pattern Alerts - newser.com
CAMP4 Therapeutics CorporationCommon Stock (NQ: - FinancialContent
3 Healthcare Companies Insiders Are Buying - The Globe and Mail
Is Camp4 Therapeutics Corporation a good long term investmentCup and Handle Formations & Low Entry Investment Portfolio - earlytimes.in
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):